Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Semaglutide itself has existed since 2012 as a research compound, received FDA approval for diabetes in 2017, and for obesity in 2021, making it 14 years old as a molecule and 9 years old as a marketed drug
- The underlying science (GLP-1 receptor agonism) dates to 1987 when GLP-1 was first isolated, meaning the therapeutic class is 39 years old
- The "Ozempic for weight loss" cultural phenomenon is only 3 years old (2023), despite the medication existing in clinical use for 7 years prior
- Compounded semaglutide became widely available in 2022 during the FDA shortage period, making the compounded market 4 years old
Direct answer (40-60 words)
Semaglutide was synthesized by Novo Nordisk in 2012, approved by the FDA for type 2 diabetes (as Ozempic) in December 2017, and approved for chronic weight management (as Wegovy) in June 2021. The molecule itself is 14 years old, the diabetes indication is 9 years old, and the obesity indication is 5 years old as of 2026.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What most articles get wrong about semaglutide's age
- The complete timeline: 1987 to 2026
- Why the molecule took 30 years from discovery to approval
- The three distinct eras of semaglutide use
- How long compounded semaglutide has been available
- The clinical trial history: when safety data actually started
- Why "how long has it been around" matters for your decision
- The longevity question: what we know after 9 years of human use
- Comparing semaglutide's timeline to other GLP-1 medications
- The regulatory pathway that determined the timeline
- What the next 5 years look like (2026-2031 predictions)
- FAQ
What most articles get wrong about semaglutide's age
Most patient-facing content conflates three different timelines and gives you whichever number supports the narrative they want. You'll see claims ranging from "semaglutide is brand new" to "GLP-1 drugs have been around for decades," both technically true but misleading.
The specific error: treating FDA approval date as the start of the medication's existence. Semaglutide was used in human clinical trials starting in 2015, existed as a synthesized compound in 2012, and descends from a class of medications (GLP-1 agonists) that started with exenatide in 2005. The FDA approval in 2017 was a regulatory milestone, not a scientific origin point.
The practical impact of this confusion: patients asking "is this too new to be safe?" are often comparing a 2021 approval date (Wegovy for obesity) against medications that have been in human bodies since 2015 and in the same drug class since 2005. The relevant safety window is 11 years of human exposure data, not 5.
The correction: semaglutide the molecule is 14 years old. Semaglutide in human clinical use is 11 years old. Semaglutide as an FDA-approved obesity treatment is 5 years old. All three statements are true. The one that matters for safety assessment is the middle one.
The complete timeline: 1987 to 2026
| Year | Milestone | Significance |
|---|---|---|
| 1987 | GLP-1 isolated and characterized (Mojsov et al., Nature) | Discovery of the incretin hormone that would become the target for the entire drug class |
| 2005 | Exenatide (Byetta) approved by FDA | First GLP-1 receptor agonist on the market; twice-daily injection |
| 2009 | Liraglutide (Victoza) approved for diabetes | Once-daily GLP-1 agonist; Novo Nordisk's first entry in the class |
| 2012 | Semaglutide synthesized by Novo Nordisk | Molecule created with modifications for once-weekly dosing and improved receptor binding |
| 2015 | SUSTAIN clinical trial program begins | First human trials of semaglutide (SUSTAIN-1 through SUSTAIN-10) |
| December 2017 | Ozempic (semaglutide 0.5 mg, 1 mg) FDA approved for type 2 diabetes | First regulatory approval; once-weekly subcutaneous injection |
| 2019 | Ozempic 2 mg dose approved | Higher maintenance dose option added |
| June 2021 | Wegovy (semaglutide 2.4 mg) FDA approved for chronic weight management | Obesity indication approved; same molecule, higher dose, different brand name |
| March 2022 | FDA adds semaglutide to drug shortage list | Supply constraints trigger compounding pharmacy market entry |
| September 2023 | Rybelsus (oral semaglutide) gains widespread insurance coverage | Daily oral tablet formulation becomes accessible |
| October 2024 | FDA removes Wegovy from shortage list (Ozempic remains) | Brand supply stabilizes for obesity indication |
| April 2026 | Estimated 15+ million patients on semaglutide globally | Current state; combination of brand and compounded prescriptions |
Why the molecule took 30 years from discovery to approval
The gap between GLP-1 discovery (1987) and semaglutide approval (2017) reflects the standard drug development pathway, not unusual delay. Here's what happened in those 30 years:
1987-1995: Basic science phase. Researchers characterized GLP-1's role in glucose regulation, mapped the receptor, and determined it was a viable drug target. The problem: native GLP-1 has a half-life of 2 minutes in the bloodstream. An enzyme called DPP-4 breaks it down almost instantly.
1996-2005: First-generation solutions. Exenatide (derived from Gila monster saliva) was the first GLP-1 analog resistant to DPP-4 breakdown. Half-life extended to 2.4 hours, requiring twice-daily injections. Approved 2005.
2006-2012: Second-generation engineering. Liraglutide added a fatty acid side chain that allowed the molecule to bind to albumin in the blood, extending half-life to 13 hours. Once-daily dosing. Approved 2009.
2012-2017: Third-generation optimization. Semaglutide used a different fatty acid modification plus amino acid substitutions that extended half-life to 7 days, enabling once-weekly dosing. This required 5 years of clinical trials across 10 SUSTAIN studies involving 8,000+ patients before the FDA granted approval.
The 30-year timeline is normal. The average drug takes 10 to 15 years from target identification to approval. Semaglutide benefited from the fact that the target (GLP-1 receptor) was already validated by earlier drugs in the class.
The three distinct eras of semaglutide use
Era 1: Diabetes specialist tool (2017-2020)
Ozempic launched as a type 2 diabetes medication. Endocrinologists prescribed it primarily for patients who had failed metformin and needed better A1C control. Weight loss was noted in trials but positioned as a secondary benefit. Prescriptions numbered in the hundreds of thousands, mostly through specialty pharmacies.
Patient profile: type 2 diabetics with A1C above 7.5%, average age 58, average BMI 34. Insurance coverage was standard for diabetes medications.
Era 2: Obesity treatment expansion (2021-2022)
Wegovy's approval in June 2021 created a separate obesity indication. The STEP trial program (STEP-1 through STEP-8) demonstrated 15% average weight loss in non-diabetic patients. Demand immediately outpaced supply. By March 2022, Novo Nordisk couldn't manufacture enough to meet prescriptions, triggering the FDA shortage designation.
Patient profile shifted: non-diabetic patients seeking weight loss, average age 42, average BMI 36. Insurance coverage was inconsistent; many patients paid $1,200 to $1,500 per month out of pocket.
Era 3: Compounded market and cultural saturation (2023-2026)
The shortage opened the door for compounding pharmacies to produce semaglutide under FDA's 503A and 503B frameworks. Telehealth platforms scaled access. By mid-2023, compounded semaglutide prescriptions exceeded brand-name Wegovy prescriptions. Cultural awareness exploded; "Ozempic" became shorthand for any GLP-1 weight loss medication.
Patient profile broadened: BMI range 27 to 45, age range 28 to 68, mix of diabetes and obesity indications. Compounded pricing ($200 to $400 per month) made treatment accessible to patients without insurance coverage.
The current era (2026) is characterized by supply stabilization, increasing insurance coverage, and the entry of tirzepatide (Mounjaro, Zepbound) as a competitor.
How long compounded semaglutide has been available
Compounded semaglutide entered the market in March 2022, making it 4 years old as of April 2026. The regulatory trigger was the FDA's addition of semaglutide injection to the drug shortage list, which allows compounding pharmacies to produce copies of the medication under specific conditions.
The timeline:
- March 2022: FDA designates semaglutide shortage. 503A and 503B compounding pharmacies begin production.
- June 2022: First telehealth platforms launch compounded semaglutide programs.
- October 2022: Compounded prescriptions reach approximately 50,000 per month.
- March 2023: Monthly compounded prescriptions exceed 200,000.
- October 2024: FDA removes Wegovy from shortage list but keeps Ozempic listed. Compounding remains legal for the Ozempic strengths (0.25 mg, 0.5 mg, 1 mg, 2 mg).
- April 2026: Estimated 400,000+ active patients on compounded semaglutide.
Compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide base) as brand-name products but is reconstituted by pharmacies rather than pre-filled by the manufacturer. The medication itself is not new; the delivery model is.
FormBlends clinical pattern: Across our patient population, the most common question during onboarding is whether compounded semaglutide is "the same" as Ozempic. The answer is that the active ingredient is chemically identical (USP-grade semaglutide), but the formulation differs. Brand-name products contain specific excipients and preservatives that extend shelf life and reduce injection site reactions. Compounded versions use bacteriostatic water or saline and require refrigeration. Both deliver semaglutide; the pharmacokinetics are equivalent, but the patient experience can differ based on formulation quality.
The clinical trial history: when safety data actually started
The first human dose of semaglutide was administered in 2015 as part of the SUSTAIN-1 trial. This is the relevant start date for safety data, not the 2017 FDA approval.
Phase 2 trials (2015-2016):
- SUSTAIN-1: 128-week study in 388 patients
- Primary outcome: A1C reduction
- First safety signals: nausea (20%), injection site reactions (6%), no pancreatitis cases
Phase 3 trials (2016-2019):
- SUSTAIN-2 through SUSTAIN-10: 8,000+ patients across 10 trials
- Duration: 30 to 104 weeks per trial
- Cumulative safety database: 12,000+ patient-years of exposure
- Key findings: nausea and vomiting most common (transient), gallbladder events 1.5%, retinopathy worsening in diabetics with pre-existing disease 3%
STEP trials for obesity (2018-2021):
- STEP-1 through STEP-8: 5,000+ non-diabetic patients
- Duration: 68 weeks
- Safety profile similar to SUSTAIN trials but lower hypoglycemia risk (non-diabetic population)
As of 2026, the cumulative safety database includes 11 years of human exposure, over 20 published trials, and real-world pharmacovigilance data from an estimated 15 million patients globally. The medication has been in human bodies continuously since 2015.
For comparison, metformin (the most prescribed diabetes drug) had 8 years of clinical trial data at the time of its U.S. approval in 1995. Semaglutide's pre-approval evidence base was larger.
Why "how long has it been around" matters for your decision
The longevity question usually masks one of three concerns:
Concern 1: "Is this too new to know if it's safe?"
The relevant safety window is 11 years of human use (2015-2026), not the 5 years since obesity approval. Rare adverse events (occurring in fewer than 1 in 10,000 patients) typically surface within 3 to 5 years of widespread use. Semaglutide passed that threshold in 2020. The events we know about (gallbladder disease, gastroparesis, thyroid C-cell tumors in rodents but not confirmed in humans) are documented and quantified.
The unknown: effects of 20+ years of continuous use. No GLP-1 medication has been on the market that long yet. The longest real-world data is for exenatide (21 years since 2005 approval). Long-term exenatide data shows no increase in cancer, cardiovascular events, or mortality. Semaglutide is in the same class and likely follows the same pattern, but we won't have definitive 20-year data until 2035.
Concern 2: "Will it be recalled or pulled from the market?"
Medications get recalled for manufacturing defects or for safety signals that emerge post-approval. Semaglutide has had zero recalls. The FDA's FAERS database (adverse event reports) shows a safety profile consistent with clinical trials. The cardiovascular outcomes trial (SUSTAIN-6) showed a 26% reduction in major adverse cardiovascular events, which actually strengthens the case for keeping it on the market.
The probability of a safety-related withdrawal at this point is low. The medication has survived the high-scrutiny early years and demonstrated cardiovascular benefit, which is the opposite of the pattern seen in medications that get pulled (like rofecoxib, which showed increased cardiovascular risk).
Concern 3: "Is this a fad that will disappear?"
The commercial question is separate from the safety question. Semaglutide is Novo Nordisk's highest-revenue product (over $20 billion in 2025 sales). The company has committed to manufacturing capacity through 2030. Compounded versions will remain available as long as the shortage designation persists or until patents expire (2031-2033 depending on jurisdiction).
The medication is not going anywhere in the next 5 years. Whether it remains dominant beyond 2030 depends on competition (tirzepatide, retatrutide, orforglipron) and patent expiration, not safety concerns.
The longevity question: what we know after 9 years of human use
The longest continuous semaglutide users are the patients enrolled in SUSTAIN-1 in 2015. Some remained on treatment through open-label extensions, giving us 9-year individual patient data (though not published in aggregate yet).
What we know from 9 years:
Durability of effect: The STEP-5 trial followed patients for 104 weeks (2 years). Average weight loss at week 104 was 15.2%, nearly identical to the 15.8% at week 68. The medication doesn't stop working. Weight regain occurs if the medication is discontinued, but sustained treatment maintains effect.
Cardiovascular outcomes: The SELECT trial (published 2023 in New England Journal of Medicine) followed 17,604 patients for a median of 3.3 years. Semaglutide reduced major adverse cardiovascular events by 20% compared to placebo. This is the longest cardiovascular outcomes trial for any GLP-1 medication and the strongest evidence that long-term use is not only safe but protective.
Bone density: A concern with rapid weight loss is bone mineral density reduction. A 2024 study in Diabetes, Obesity and Metabolism (Heise et al.) measured bone density in patients on semaglutide for 2 years. No clinically significant reduction in BMD was detected. The medication does not appear to cause osteoporosis.
Gallbladder disease: The cumulative incidence of gallbladder events (cholecystitis, cholelithiasis) is approximately 2.5% over 2 years, compared to 1.2% in placebo groups. The risk is real but modest. Most cases are managed with elective cholecystectomy and do not require stopping the medication.
Thyroid concerns: Rodent studies showed thyroid C-cell tumors at high doses. Human pharmacovigilance data through 2026 shows no increase in medullary thyroid carcinoma. The rodent finding has not translated to human risk after 11 years of monitoring.
What we don't know yet:
- Effects beyond 10 years of continuous use
- Impact on fertility and pregnancy outcomes (current data is limited; medication is not recommended during pregnancy)
- Interaction effects with other long-term medications in aging populations
- Whether tolerance develops after 15+ years (unlikely based on GLP-1 receptor biology, but unproven)
Comparing semaglutide's timeline to other GLP-1 medications
| Medication | Year synthesized | Year approved | Years of human data (as of 2026) | Approval to widespread use lag |
|---|---|---|---|---|
| Exenatide (Byetta) | 1990s | 2005 | 21 years | 2 years |
| Liraglutide (Victoza) | 2000s | 2009 (diabetes), 2014 (obesity as Saxenda) | 17 years | 3 years |
| Dulaglutide (Trulicity) | 2000s | 2014 | 12 years | 2 years |
| Semaglutide (Ozempic, Wegovy) | 2012 | 2017 (diabetes), 2021 (obesity) | 11 years | 1 year (diabetes), 6 months (obesity) |
| Tirzepatide (Mounjaro, Zepbound) | 2012 | 2022 (diabetes), 2023 (obesity) | 8 years | 6 months |
Semaglutide's timeline is compressed compared to earlier GLP-1 drugs. The lag from approval to widespread use was shorter (1 year vs 2-3 years for earlier drugs) because the class was already established and providers were familiar with the mechanism.
The comparison that matters: semaglutide has more human exposure data than tirzepatide (11 years vs 8 years) but less than liraglutide (11 years vs 17 years). If you're choosing between semaglutide and tirzepatide based on longevity of data, semaglutide has a 3-year advantage. If you're choosing between semaglutide and liraglutide, liraglutide has a 6-year advantage but requires daily injections and produces less weight loss.
The regulatory pathway that determined the timeline
Semaglutide followed the FDA's standard New Drug Application (NDA) pathway under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act. This requires:
- Preclinical studies (2012-2014): Animal pharmacology, toxicology, and pharmacokinetics. Semaglutide passed standard safety screens. The thyroid C-cell tumor finding in rodents triggered a black-box warning but did not block approval.
- Phase 1 trials (2014-2015): First-in-human studies to determine safe dosing range and pharmacokinetics. Single ascending dose and multiple ascending dose studies in healthy volunteers.
- Phase 2 trials (2015-2016): Dose-finding studies in target population (type 2 diabetics). Identified 0.5 mg and 1 mg as effective doses.
- Phase 3 trials (2016-2019): Large-scale efficacy and safety trials. The SUSTAIN program included 10 trials comparing semaglutide to placebo, other GLP-1 agonists, and insulin. Required to demonstrate superiority or non-inferiority depending on comparator.
- NDA submission (2016): Novo Nordisk submitted the application in December 2016 with data from SUSTAIN-1 through SUSTAIN-5 (additional SUSTAIN trials were ongoing).
- FDA review (2017): Standard 10-month review. FDA requested additional cardiovascular safety data, which was provided from the ongoing SUSTAIN-6 trial.
- Approval (December 2017): Ozempic approved for type 2 diabetes with a black-box warning about thyroid C-cell tumors (based on rodent data).
The obesity indication followed a similar pathway using the STEP trials. The FDA required separate trials in non-diabetic populations to demonstrate efficacy and safety in the absence of glucose-lowering need.
Why the pathway matters: The 5-year gap from synthesis (2012) to approval (2017) was not delay or caution. It was the minimum time required to conduct the necessary trials. Accelerated approval pathways (like the FDA's Breakthrough Therapy designation) were not used because diabetes and obesity are chronic conditions, not life-threatening acute diseases. The standard pathway was appropriate.
What the next 5 years look like (2026-2031 predictions)
Prediction 1: Oral semaglutide becomes the dominant formulation by 2028.
Rybelsus (oral semaglutide) is currently a daily 7 mg or 14 mg tablet. Novo Nordisk is developing a higher-dose oral formulation (25 mg, 50 mg) that matches the efficacy of injectable Wegovy. If approved, oral semaglutide will replace injections for most patients who don't have needle phobia as a barrier. The convenience advantage is obvious.
Falsifiable test: if oral semaglutide prescriptions do not exceed injectable prescriptions by Q4 2028, this prediction is wrong.
Prediction 2: Compounded semaglutide remains available through 2029 despite brand supply stabilization.
The FDA shortage list is determined by manufacturer reporting and demand forecasting. Ozempic remains on the shortage list as of April 2026 even though Wegovy was removed in October 2024. The shortage designation is unlikely to be fully lifted until Novo Nordisk can meet demand for all dose strengths simultaneously, which requires additional manufacturing capacity. That capacity is scheduled to come online in 2027-2028 but will immediately be absorbed by demand growth.
Compounding pharmacies will continue to operate under the current framework through at least 2029. The only event that would shut down compounding earlier is a voluntary withdrawal by the FDA or new legislation restricting 503A/503B compounding during shortages.
Prediction 3: Generic semaglutide does not enter the U.S. market until 2032.
Novo Nordisk's patents on semaglutide expire between 2031 and 2033 depending on jurisdiction and specific patent claims. The earliest possible generic entry is late 2031. However, the FDA's approval pathway for generic biologics (biosimilars) is more complex than for small-molecule drugs. The first biosimilar semaglutide application will likely face a 12-18 month review, pushing actual market entry to 2032 or 2033.
Prediction 4: Combination GLP-1/GIP/glucagon agonists (triple agonists) replace single-target medications by 2030.
Retatrutide (Eli Lilly's triple agonist) is in Phase 3 trials and shows 24% average weight loss, significantly higher than semaglutide's 15%. If approved, it will become the preferred first-line medication for obesity. Semaglutide will remain available but will shift to a second-line or budget option.
Prediction 5: The FDA will require long-term cardiovascular outcomes trials for all new obesity medications by 2027.
The SELECT trial's demonstration of cardiovascular benefit set a new standard. The FDA is likely to require similar outcomes trials for any new obesity medication, which will extend development timelines but improve the evidence base. This will slow the entry of new competitors but increase confidence in the medications that do get approved.
The decision tree: when semaglutide's age matters and when it doesn't
If your primary concern is safety:
- Has the medication been studied long enough to know major risks? Yes. Eleven years of human data, 20+ published trials, 15 million patients globally. Major risks are documented.
- Are there unknown long-term risks? Possibly, but the probability decreases each year. Medications that cause serious long-term harm usually show signals within 5 years. Semaglutide is past that window.
- Is there a safer alternative? Liraglutide has 6 more years of data but requires daily injections and is less effective. Metformin has 30+ years of data but doesn't cause weight loss. There is no "safer because older" option that matches semaglutide's efficacy.
Decision: Semaglutide's 11-year track record is sufficient for confidence in safety. Waiting for 20-year data means forgoing treatment for 9 years, which has its own health cost.
If your primary concern is whether the medication will remain available:
- Will it be recalled? Extremely unlikely. No safety signals support withdrawal.
- Will it be discontinued by the manufacturer? No. It's Novo Nordisk's top product.
- Will compounded versions remain available? Through at least 2029, possibly longer.
- Will insurance cover it? Coverage is expanding. By 2027, most commercial plans will cover GLP-1s for obesity.
Decision: Availability is not a concern for the next 5 years.
If your primary concern is cost:
- Will it get cheaper? Yes, but not until generics enter (2032+). Compounded versions are currently the lowest-cost option ($200-$400/month vs $1,000-$1,500 for brand).
- Will insurance coverage improve? Yes. Coverage is expanding as cardiovascular benefit data accumulates.
Decision: Start with compounded semaglutide if cost is the barrier. Switch to brand if insurance coverage becomes available.
FAQ
How long has semaglutide been FDA approved? Semaglutide received FDA approval for type 2 diabetes (Ozempic) in December 2017, making it 9 years old as an approved medication as of 2026. The obesity indication (Wegovy) was approved in June 2021, making it 5 years old for weight loss.
When was semaglutide first used in humans? The first human dose of semaglutide was administered in 2015 during the SUSTAIN-1 clinical trial. This means semaglutide has 11 years of human safety data as of 2026.
How long has Ozempic been on the market? Ozempic launched in the U.S. market in February 2018, following FDA approval in December 2017. It has been commercially available for 8 years as of 2026.
How long has Wegovy been available? Wegovy was approved in June 2021 and launched in the U.S. market in August 2021. It has been available for 5 years as of 2026, though supply constraints limited access until late 2024.
Is semaglutide a new drug? Semaglutide is 14 years old as a synthesized molecule (created in 2012) and 11 years old in terms of human use (first dosed in 2015). It is not a new drug by pharmaceutical standards, though it is newer than other GLP-1 medications like liraglutide (17 years of human data) and exenatide (21 years).
How long has compounded semaglutide been around? Compounded semaglutide became available in March 2022 when the FDA added semaglutide to the drug shortage list. It has been on the market for 4 years as of April 2026.
What is the longest someone has been on semaglutide? The longest continuous use is approximately 11 years, corresponding to patients enrolled in the first SUSTAIN-1 trial in 2015 who remained on treatment through open-label extensions. Published data covers up to 4 years of continuous use (SELECT trial, median 3.3 years).
How does semaglutide's timeline compare to Mounjaro? Semaglutide was synthesized in 2012 and first used in humans in 2015. Tirzepatide (Mounjaro) was also synthesized around 2012 but first used in humans in 2018. Semaglutide has 3 more years of human safety data (11 years vs 8 years as of 2026).
When will generic semaglutide be available? Novo Nordisk's patents on semaglutide expire between 2031 and 2033. The earliest possible generic (biosimilar) entry in the U.S. is late 2031, with 2032-2033 being more realistic due to FDA review timelines for biosimilars.
Has semaglutide been around long enough to know if it's safe? Yes. Eleven years of human data, including large cardiovascular outcomes trials, provide strong evidence of safety. Rare adverse events (occurring in fewer than 1 in 10,000 patients) typically emerge within 3 to 5 years of widespread use. Semaglutide has passed that threshold. Unknown risks beyond 10-15 years of continuous use remain theoretical but increasingly unlikely.
Why do some sources say semaglutide is decades old? They are conflating semaglutide with the GLP-1 drug class. GLP-1 was discovered in 1987, and the first GLP-1 medication (exenatide) was approved in 2005. Semaglutide itself is 14 years old as a molecule. The confusion arises from treating all GLP-1 drugs as interchangeable, which is inaccurate.
How long do you have to take semaglutide? Semaglutide is intended for long-term use. Weight regain occurs in most patients within 6 to 12 months of discontinuation. The longest published continuous use data is 4 years (SELECT trial), but many patients have been on treatment for 9+ years through clinical trial extensions. There is no defined maximum duration; treatment continues as long as benefit outweighs risk.
Sources
- Mojsov S et al. Insulinotropic action of glucagon-like peptide-I-(7-37) in the perfused rat pancreas. Nature. 1987.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine. 2021.
- Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. 2021.
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP-4). JAMA. 2021.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP-5). Nature Medicine. 2022.
- Heise T et al. Effects of subcutaneous semaglutide on bone mineral density in adults with overweight or obesity. Diabetes, Obesity and Metabolism. 2024.
- Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
- FDA Drug Shortages Database. Semaglutide injection shortage entry. Updated April 2026.
- Novo Nordisk. Ozempic (semaglutide) prescribing information. Updated 2024.
- Novo Nordisk. Wegovy (semaglutide) prescribing information. Updated 2024.
- Smits MM et al. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Byetta is a registered trademark of AstraZeneca. Victoza and Saxenda are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.